REDLAMP 15: Outcomes for Patients with Mantle Cell Lymphoma after Ibrutinib
While ibrutinib represents undeniable progress in the treatment of mantle cell lymphoma, the outcomes and ideal management of patients that experience ibrutinib failure are unclear. In a study recently published in Blood, Dr. Peter Martin discusses findings from a recent observational study from 15 sites on patients who experienced lymphoma progression while receiving ibrutinib.